WALTHAM, Mass.--(BUSINESS WIRE)--Synageva BioPharma Corp., a privately held biopharmaceutical company, announced that the U.S. Food and Drug Administration (FDA) has granted orphan drug designation for SBC-102, the Company’s enzyme replacement therapy in development to treat Lysosomal Acid Lipase (LAL) Deficiency, also known as Wolman Disease and Cholesteryl Ester Storage Disease (CESD), a condition for which there is currently no approved treatment.
